←
Scendea2,358 posts
Scendea avatar

Scendea

@scendea

Scendea is a leading product development and regulatory consulting practice serving the pharmaceutical and biotechnology industry.

◷ Joined May 2020▧ 2,305 Photos and videos
Scendea avatar
Scendea@scendea·12h

Tackling antimicrobial resistance is one of modern medicine's most urgent unmet needs. - Scendea is proud to support innovators navigating global regulatory pathways to bring novel antimicrobials to patients. 🔗 scendea.com - #AMR #DrugDevelopment #Biotech

Post attachment
Scendea avatar
Scendea@scendea·Nov 17

Partnering is officially open for BIO Partnering @ JPM Week 2027 — and Scendea is proud to be a conference sponsor! - Search “Scendea” directly in the BIO Partnering™ portal to request a 1-on-1 meeting bpjw.bio.org/bio-partnering

Post attachment
Scendea avatar
Scendea@scendea·Nov 17

The EMA has updated its information on the implementation of the new EU Pharmaceutical Legislation, representing a major overhaul of the EU regulatory framework for medicines. - Book a call to discuss development programme and reg strategy implications: scendea.com/contact

Post attachmentPost attachmentPost attachmentPost attachment
Scendea avatar
Scendea@scendea·Nov 14

On World Diabetes Day, we acknowledge the researchers, healthcare professionals and life sciences organisations whose continued work and innovation are helping to advance our understanding of diabetes and improve treatment and care. - #WorldDiabetesDay #LifeSciences

Post attachment
Scendea avatar
Scendea@scendea·Nov 13

The MHRA guidance on the use of non-OECD MAD non-clinical data sets out a risk-proportionate framework for assessing such data in UK CTA applications. - Speak to our experts about what the MHRA framework could mean for your development strategy: scendea.com/contact

Post attachmentPost attachmentPost attachmentPost attachment
Scendea avatar
Scendea@scendea·Nov 12

Our webinar with SoPE explores why early agency feedback can help emerging companies challenge assumptions and avoid unnecessary development activity or expenditure. - 🎥 Watch Strategic FDA & EMA Interactions: Practical Approaches to De-Risk Development: youtube.com/watch?v=zHTM4sTI…

Post attachment
Scendea avatar
Scendea@scendea·Nov 10

The MHRA and HRA have published findings from a six-month pilot evaluating Inclusion and Diversity Plans submitted alongside REC applications. - Talk to our experts about evolving UK expectations impacting your clinical development programme: scendea.com/contact

Post attachmentPost attachmentPost attachmentPost attachment
Scendea avatar
Scendea@scendea·Nov 6

BioLabs University of Toronto event "Drug Development Regulatory Pathways across the Globe" on November 19th at BioLabs University of Toronto.

Scendea avatar
Scendea@scendea·Nov 5

The FDA has announced the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program designed to accelerate medical innovation and deliver breakthrough treatments. - Get in touch today to speak to our experts: scendea.com/contact

Post attachmentPost attachmentPost attachmentPost attachment
Scendea avatar
Scendea@scendea·Nov 5

Would you know when to approach the FDA or EMA, before a critical development decision becomes expensive to change? - 🎥 Watch our recent webinar - Strategic FDA & EMA Interactions: Practical Approaches to De-Risk Development: youtube.com/watch?v=zHTM4sTI…

Post attachment